Plain-English translation of NCT07345585 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial studied whether Lactobacillus rhamnosus GG, a type of beneficial bacteria, could help children with autism spectrum disorder who also suffer from digestive issues like constipation or diarrhea. Researchers believed that imbalances in the gut bacteria of children with autism might contribute to both their digestive symptoms and autism-related behaviors. The trial tested whether this medication could restore healthy gut bacteria and improve symptoms.
Children with autism often experience digestive problems that make their symptoms worse and create stress for their families. Recent research suggested that an imbalance in gut bacteria might play a role in both autism and these digestive issues, so scientists wanted to test whether restoring healthy bacteria with this treatment could help.
Children enrolled in this trial received either the probiotic supplement Lactobacillus rhamnosus GG or a placebo (inactive pill) that looked identical, so neither the child nor the researchers knew which treatment they were receiving. Participants took their assigned treatment daily over a set period while researchers monitored their digestive symptoms and overall well-being to see whether the medication made a difference.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
Italy